GlassScriptPhysician profile
Steven J Saccaro
NPI 1194728543
$3,264.16
in general payments reported to CMS, 2019-2025
39 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $23.86 · 2021: $343 · 2022: $278 · 2023: $382 · 2024: $1,086 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,305 · Education: $14.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,305.24 |
| Education | $14.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $419.81 | 2019-2025 | |
| Celgene Corporation | $392.96 | 2019-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $366.41 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Gilead Sciences, INC. | $221.95 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $221.24 | 2022-2025 | Enhertu, Injectafer |
| Pfizer INC. | $217.81 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $201.42 | 2019-2025 | Opdivo, Opdualag |
| Emd Serono, INC. | $131.48 | 2024 | |
| Eisai INC. | $112.76 | 2019-2024 | |
| Genzyme Corporation | $94.49 | 2023-2025 | |
| Abbvie INC. | $77.62 | 2024-2025 | |
| Genentech USA, INC. | $74.03 | 2019-2024 | Itovebi, Perjeta, Phesgo |
| Amgen INC. | $63.82 | 2019-2022 | |
| Astellas Pharma US INC | $61.43 | 2021-2025 | Xtandi |
| Alexion Pharmaceuticals, INC. | $61.40 | 2019-2024 | Ultomiris |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $54.51 | 2025 | Lorbrena, Braftovi, Mektovi |
| Pharmacyclics LLC, An Abbvie Company | $37.94 | 2023 | Imbruvica |
| Beigene USA, INC. | $35.79 | 2022-2023 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $33.11 | 2019-2025 | |
| Kite Pharma, INC. | $28.99 | 2021 | |
| Janssen Biotech, INC. | $28.77 | 2021-2023 | Darzalex |
| Sobi, INC | $27.90 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.67 | 2025 | Alunbrig |
| Eusa Pharma (US) LLC | $26.62 | 2019 | |
| Glaxosmithkline, LLC. | $25.71 | 2025 | Jemperli, Zejula |
| Regeneron Healthcare Solutions, INC. | $25.02 | 2024 | Libtayo |
| Geron Corporation | $22.61 | 2025 | Rytelo |
| Bayer Healthcare Pharmaceuticals INC. | $19.52 | 2024 | |
| Epizyme, INC. | $18.98 | 2021 | |
| Ethicon US, LLC | $18.23 | 2019 | |
| Seagen INC. | $17.13 | 2022 | |
| Progenics Pharmaceuticals, INC. | $16.81 | 2021 | |
| Servier Pharmaceuticals LLC | $16.21 | 2024 | |
| Veracyte, INC. | $15.94 | 2024 | |
| Stemline Therapeutics INC. | $13.09 | 2024 | Orserdu |
| Aveo Pharmaceuticals, INC. | $12.67 | 2021 | |
| Cti Biopharma Corp. | $11.87 | 2022 | |
| Blueprint Medicines Corporation | $11.44 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Saccaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.